Early Stage Type 1 Diabetes Initial Screen
DBS immunoassay screen for early Type 1 diabetes: detects GAD65, IA-2, ZnT8, and insulin autoantibodies; reflexes to individual autoantibody identification.
Accessed through the UncoverT1D Sponsored Testing Program•Sponsored by Sanofi•Performed by Revvity Omics, Inc.
Designed to help patients understand the purpose of testing and what to expect.
For patients
What this test and program do
This no-cost, sponsored program helps evaluate early stage Type 1 diabetes by checking four autoantibodies (GAD65, IA-2, ZnT8, and insulin). Testing is performed by Revvity Omics, with reflex to identify individual antibodies when indicated. Your clinician will determine if this pathway is right for you and explain results and next steps.
Who this may help
Could this be right for you or your family?
- You have a valid Canadian health card (or Interim Health Program card).
- You live in Canada (main residence in Canada, or you’re currently in Canada on a visa or similar).
- You (or your caregiver) have provided informed consent.
- You meet the screening criteria your clinician uses for this program.
- You do not already have publicly covered access to comprehensive 4-autoantibody testing.
What to expect
How the process works
- 1
Discuss & enroll
Your clinician confirms you’re eligible, explains the program, and completes consent.
- 2
Give sample
Follow the kit instructions; your clinic handles labeling and shipping.
- 3
Get results
Your clinician receives the report and reviews what it means and any next steps (including confirmatory or follow-up testing if needed).
Cost & coverage
Understanding potential costs
If you qualify for this program, the sponsor works with the laboratory to help make testing more affordable. Many patients pay little or no out-of-pocket cost. Your exact cost will depend on your insurance coverage and the specific criteria of the program, and the lab can explain what to expect before your sample is processed.
Quality & privacy
How your sample and information are handled
Testing is performed by Revvity Omics, Inc., a CLIA-certified laboratory (CLIA 39D0673919). Your sample is processed using validated methods and quality controls to support reliable genetic results.
Your health information is handled under privacy and security practices that are intended to align with applicable regulations. For program- and lab-specific details, review the privacy information provided by the laboratory and sponsor.
FAQ
Common questions about this program
What is this program?
A no-cost, sponsored testing program that checks for early autoimmune Type 1 diabetes using four autoantibodies (GAD65, IA-2, ZnT8, insulin).
Who can use it?
Patients in Canada with a valid health card (or Interim Health Program card) who meet screening criteria set by their clinician.
What sample is needed?
A small dried blood spot (DBS) collected with a simple kit.
How long do results take?
Timing varies; your clinician will let you know when to expect results.
Are confirmatory or follow-up tests covered?
Yes—when clinically appropriate, confirmatory and follow-up testing are available at no cost.
Will I be billed?
No. Eligible patients receive testing at no cost through this sponsored program.
Who gets my results?
Your clinician receives the report and explains what it means and next steps.
Questions to ask your doctor about Early Stage Type 1 Diabetes Initial Screen
- Do you think this test is appropriate for me based on my symptoms and history?
- How could the results of this test change my diagnosis or treatment plan?
- What are the potential limitations of this test that I should understand?
- Should any of my family members also be tested based on my results?
- How will we follow up after the results are available?
Notes
See an issue with this program?